Form 4 for BRVE Braveheart Bio, Inc.
Accepted 2026-08-07 16:31:15 ET · period of report 2026-08-05 · accession 0001470831-26-000801 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-07 16:31 | 2026-08-07 | BRVE | Viehbacher Christopher | Dir | P - Purchase | $18.00 | +83.3K | 609.5K | +16% | +$1.50M |
| D | 2026-08-07 16:31 | 2026-08-05 | BRVE | Viehbacher Christopher | Dir | A - Grant | $0.00 | +30.0K | 30.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-07 | P | A | 83,333 | $18.00 | 609,519 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-08-05 | A | A | 30,000 | $0.00 | 30,000 | D | $18.00 · — to 2036-08-04 | 30,000 Common Stock | (F2) The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. |